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Abstract
Objectives: The aim of this study was to evaluate the
incidence of posttransplant malignancy in kidney
transplant patients and investigate the clinical and
histopathologic features of these patients.
Materials and Methods: We retrospectively reviewed
information on donor and recipient characteristics,
patient and graft survival, and cancer incidence after
transplant for 867 kidney transplant patients. Patients
with neoplasms prior to transplant were excluded. A
follow-up study estimated cancer incidence after
transplant.
Results: Neoplasms were diagnosed in 59 patients
(6.8%), 41 men and 18 women; 22 (37.3%) had skin
tumors, 19 (32.2%) had solid tumors, 10 (16.9%) had
posttransplant lymphoproliferative disorders, and 8
(13.6%) had Kaposi sarcoma. The mean age at the time
of malignant tumor diagnosis was 42.7 ± 13.6 years,
and statistically significant differences were found
between tumor groups (P < .01). The average latency
period between transplant and diagnosis of malignant
tumors was 99.8 ± 56.9 months for solid tumors, 
78.4 ± 52 months for skin tumors, 64.5 ± 48.8 months
for posttransplant lymphoproliferative disorders, and
13.5 ± 8.8 months for Kaposi sarcoma, with significant
difference found between tumor groups (P < .01). Ten
patients (16.9%) had more than 1 malignant tumor.
Eighteen patients died, with a mean time to death of
31.5 ± 22.8 months after tumor diagnosis. A significant
positive association was found between survival and
the number of tumors (P = .001); 5-year survival after
tumor diagnosis was 81% and 40% for patients with 1
malignant tumor and patients with more than 1
malignant tumor, respectively.
Conclusions: Malignancy is a common cause of death
after renal transplant. Early detection and treatment
of posttransplant malignancies is an important
challenge. Screening these patients for malignancies
posttransplant is crucial, and efforts should be
directed to define effective immunosuppressive
protocols that are associated with a lower incidence of
malignancy.
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Introduction
De novo malignancies in renal transplant recipients
are one of the leading causes of morbidity and
mortality.1 Advances in transplant surgery and new
immunosuppressive agents extend overall life
expectancy and quality of life for these patients.
Compared with the general population, certain
tumors occur more frequently in renal transplant
recipients and are associated with poor prognosis.2,3
Immunosuppressive treatment, in addition to
common risk factors, is thought to play a major role
in the development of malignancy.4 Our aim in this
study was to evaluate the incidence of posttransplant
malignancy and investigate the clinical and
histopathologic features of these patients.
Materials and Methods
Only 867 renal transplant patients who received
transplants between January 2000 and December
2015 at Başkent University Transplantation Center
were included in the study. For each patient,
information obtained included donor type and
recipient’s demographic and clinical findings: age,
sex, immunosuppressive therapy, age at transplant,
time from transplant to tumor diagnosis, survival,
and cancer incidence after transplant. Patients with
neoplasms before the transplant were excluded. A
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new case of a malignant neoplasm after the trans -
plant with pathologic confirmation was considered
as incident cancer. The study was approved by the
Başkent University Ethical Review Committee.
Statistical analyses were performed with statistical
software (SPSS for Windows, version 16.0, IBM
Corporation, SPSS Inc, Armonk, NY, USA). Cate -
gorical data were compared using the chi-squared test.
Patient survival was computed with the Kaplan-
Meier method. Statistical significance was defined by
P value less than < .05.
Results
Of the 867 patients, 63 neoplasms were diagnosed in
59 patients (6.8%) (41 men, 18 women) during the
posttransplant period. The 59 patients were followed
for a mean of 112.9 ± 34.4 months after transplant.
The mean age at transplant was 36.4 ± 1.7 years. Graft
source was deceased donors in 15 (25.4%) and living
donors in 44 patients (74.6%). The cause of end-stage
renal disease was polycystic kidney disease in 9
(15.3%), chronic glomerulonephritis in 7 (11.9%),
nephrolithiasis in 6 (10.2%), tubulointerstitial nephritis
in 5 (8.5%), Familial Mediterranean fever in 2 (3.4%),
diabetic nephropathy in 2 (3.4%), hypertensive
nephropathy in 2 (3.4%), vesicoureteral reflux disease
in 2(3.4%), unknown in 20 (33.9%), and 1 (1.7%) for
each of Alport syndrome, focal segmental glo -
merulosclerosis, and IgA nephropathy. At the time of
tumor diagnosis, 35 patients (59.3%) were receiving
cyclosporine (CsA), 15 (25.4%) were receiving
tacrolimus, and 9 (15.3) were receiving sirolimus-
based immunosuppressive therapy.
We analyzed posttransplant tumors in 4 main
groups. Of the 59 patients, 22 (37.3%) had skin
tumors, 19 (32.2%) had solid-organ tumors, 10
(16.9%) had posttransplant lymphoproliferative
disorders (PTLD), and 8 (13.6%) had Kaposi sarcoma
(KS). Of the 22 patients with skin tumors, 12 had
squamous cell carcinoma (SCC), and 10 had basal cell
carcinoma (BCC). Most of the skin tumors were
located in the head and neck area (Table 1). Two of
the SCCs were verrucous carcinoma, and 2 were
carcinoma in situ; others were mostly well-dif -
ferentiated. Of 10 BCCs, 7 were nodular, 1 was
metatypical, and 2 were mixed nodular and superficial
histological subtypes. Of the 8 patients with KS, 3 had
lesions limited to skin, 1 was restricted to the
gastrointestinal system, 1 was skin and lymph node,
1 was skin and gastrointestinal system, and 2 had
disseminated lesions to more than 2 organs.
Histologic examination showed tumor stage in 1,
plaque stage in 3, and patch stage in 2 patients with
KS localized to skin. Immunohistochemically, only 6
of the 8 KS lesions showed positive expression of
human herpes virus 8 antibody.
In the solid-organ tumor group, the most frequent
neoplasms were urinary tract cancers (9 patients),
followed by thyroid gland cancers (4 patients),
gastrointestinal tract cancers (2 patients), and
gynecological tract cancers (2 patients). Only 1
patient developed lung cancer (Table 1). The most
common urinary tract cancers were located in the
kidney (3 native kidneys and 3 renal allografts). Two
of 3 native kidney cancers were diagnosed as clear
cell type renal cell carcinoma (RCC) and the
remaining 1 was diagnosed as papillary type RCC.
Within renal allografts, we detected 2 clear cell RCC
and 1 mucinous RCC. Nephron-sparing surgery was
performed in 2 of the 3 renal allografts with RCC.
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Abbreviations: BCC, basal cell carcinoma; DCIS, ductal carcinoma in situ;
LCIS, lobular carcinoma in situ; PTLD, posttransplant lymphoproliferative
disorders; PTMC, papillary thyroid microcarcinoma; RCC, renal cell
carcinoma; SCC, squamous cell carcinoma; TCC, Transitional cell carcinoma
Table 1. Types of De Novo Malignancies
Localization and Type of Tumor N (%)
SKIN TUMORS 22 (37.3%)
SCC
Head and neck 9
Trunk 2
Limbs 1
BCC
Head and neck 7
Trunk 3
SOLID-ORGAN TUMORS 19 (32.2%)
Native kidney RCC 3
Allograft kidney RCC 3
Bladder TCC 1
Ureter-bladder anastomosis site SCC 1
Prostate adenocarcinoma 1
Thyroid gland PTMC 4
Billiary tract adenocarcinoma 2
Servix uteri SCC 1
Breast DCIS/LCIS 1
Lung small cell carcinoma 1
PTLD 10 (16.9%)
Extralymphoid site
Monomorphic B cell 5
Monomorphic T cell 1
Lymphoid 
MonomorphicBcell 1
Renal allograft
Polimorphic B-cell type 2
Early stage 1
KAPOSI SARCOMA
Skin only 3
Gastrointestinal system only 1
Skin and lymph node 1
Skin and gastrointestinal system 1
Disseminated lesions 2
The remaining renal allograft with RCC also had
chronic rejection at the time of tumor diagnosis.
Thus, the patient had undergone graft nephrectomy.
All of the urinary tract tumors were detected in
organ-confined stages.
All of the thyroid gland cancers were papillary
microcarcinoma, and 2 of 4 had lymph node me -
tastases. Gastrointestinal neoplasms were biliary
tract adenocarcinomas and were in stage pT4 at the
time of diagnosis in all cases.
Posttransplant lymphoproliferative disorders
were diagnosed in skin (2 patients), renal allograft 
(3 patient), and 1 patient for each of small bowel,
brain, liver, peritoneum, and lymph node. Histologic
diagnosis was polymorphic B-cell PTLD in 2
patients, monomorphic B-cell PTLD in 6 patients,
monomorphic T-cell PTLD in 1 patient, and early
lesion PTLD in 1 patient (Table 1). Epstein-Barr virus
was positive in only 8 histologic specimens. Most of
the patients with skin neoplasms, KS, and PTLD
were treated with a CsA-based immunosuppressive
regimen. However, we found that most of the
patients who had solid-organ malignancy had a
tacrolimus-based regimen (Table 2).
The mean age of patients at time of diagnosis of
malignant tumor was 42.7 ± 13.6 years. Patients who
had a diagnosis of KS were found to be younger than
the other tumor groups. Statistically significant
differences were found between tumor groups in
regard to the age at the time of diagnosis of
malignant tumor (P < .01) (Table 2). The average
latency period between transplant and time of
diagnosis of malignant tumors was 99.8 ± 56.9
months for solid-organ tumors, 78.4 ± 52 months 
for skin tumors, 64.5 ± 48.8 months for PTLD, and
13.5 ± 8.8 months for KS. Significant differences were
found between tumor groups in regard to the time
between transplant and tumor diagnosis (P < .01)
(Table 2). However, there were no significant
differences between tumor groups in regard to sex,
donor type, primary disease, or immuno suppressive
treatment.
Ten patients (16.9%) had more than 1 malignant
tumor, and 49 patients (83.1%) had only 1 malignant
tumor. Of the 10 patients who had more than 1
tumor, 1 had BCC and gingival KS, 1 had BCC and
intramucosal carcinoma in a tubular adenoma of the
colon, 2 had multiple BCCs, and 6 had KS in multiple
organs.
Of the 59 patients, 18 died at a mean time of 
31.5 ± 22.8 months after tumor diagnosis. A
significant positive association was found between
patient survival and the number of tumors (P = .001).
Overall 5-year survival after the diagnosis of the
tumor was 81% and 40% for patients with 1
malignant tumor and patients with more than 1
malignant tumor, respectively.
Discussion
The development of posttransplant malignancies is
a well-known complication after renal transplant and
the third most common cause of death in transplant
recipients.1 The overall incidence of neoplasms
following renal transplant is reported to be 4% to
18%, with a 3- to 8-fold increase in cancer risk.
However, this increase is as high as 100-fold for
virus-related cancers such as KS.2,5-7 In this study, we
analyzed the occurrence of posttransplant de novo
malignancies in our transplant center, and we found
that the incidence of the development of a malignant
tumor was 6.8% for our 867 patients.
Of all malignant tumors, skin cancers, specifically
BCCs and SCCs, are common after transplant, and
the incidence increases with time.8 The incidence of
posttransplant skin cancer varies from 2% to 68%.9-12
In the present study, incidence of skin cancers was
found to be 37.3% and compatible with the literature.
Advanced patient age is a common risk factor for
skin tumors in transplant recipients; patients aged 
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Abbreviations: CsA, cyclosporine; ISPR, immunosuppressive regimen; PTLD, posttransplant lymphoproliferative disorders; Sl, sirolimus;
T, tacrolimus
Table 2. Clinical Manifestations of De Novo Malignant Neoplasms
Tumor Groups Number of Sex, Age at Time Between ISPR Donor Type 
Cases, n (%) Men/Women Malignancy (y), Transplant and CsA/T/Sl, (Deceased/Living),
Mean ± SD Tumor Diagnosis n n
(mo), mean ± SD
Skin tumors 22 (37.3) 16/6 48.9 ± 12.2 78.4 ± 52 15/3/4 6/16
Solid organ tumors 19 (32.2) 14/5 44.37 ± 11 99.8 ± 56.9 7/9/3 5/14
PTLD 10 (16.9) 6/4 35.9 ± 10.3 64.5 ± 48.8 7/1/2 2/8
Kaposi sarcoma 8 (13.6) 5/3 30.3 ± 16 13.5 ± 8.8 6/2/0 2/6
P value > .5 > .5 .002 .004 > .5 > .5
Total 59 (100) 41/18 42.7 ± 13.6 74.6 ± 59.2 35/15/9 15/44
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> 55 years were reported to have greater risk
compared with patients < 35 years.9,12,13 Similar to the
literature, the mean age of our patients with skin
cancers was 48.9 ± 12.2 years, and it is significantly
higher than that of patients who developed other
malignant tumors. The development of skin SCC
was reported more frequently than BCC in kidney
transplant recipients.10,14 Confirming these studies,
we also found that SCC was the most common
malignant tumor, followed by BCC. In contrast, some
other studies showed higher ratios of BCC to SCC.9,11
Some cancers that are uncommon in general
populations have a tendency to develop in organ
transplant recipients. One of these uncommon
neoplasms is KS. Human herpes virus 8 associated
with KS and infection prevalence shows geographical
variation ranging from 5% in North America and
Northern Europe, to 30% in Mediterranean and
Middle East countries, and to 50% in African
regions.8,15-17 KS is reported with incidence rates
between 17.6% and 70%, which is higher in the Middle
East and Mediterranean countries compatible with the
infection prevalence.18-21 Similar to the literature, the
incidence of KS was 13.6% in our study. The age at
the time of tumor diagnosis of patients with KS was
significantly lower compared with patients from
other tumor groups. Also, the average latency period
between transplant and the diagnosis of KS was
shorter than other tumor groups, and it is compatible
with other centers’ reports that showed KS devel -
opment in the first 2 years following transplant.15,22
Kaposi sarcoma is quite often limited to the skin in
transplant recipients. However, visceral involvement
tends to be associated with worse outcome and
occurs in 10% of patients.23 Contrary to the literature,
most of our patients with the diagnosis of KS had
visceral involvement. In the KS group, 75% of our
patients had CsA-based immunosuppressive regimen.
It has been reported that patients who received CsA
were at a higher incidence of developing KS.24 Penn
also suggested similar reports that explained the
increased incidence of KS with the use of CsA.25
Barrett and associates reported higher frequencies of
KS and PTLD for recipients treated with CsA
compared with patients who were not receiving CsA
treatment.26 Piselli and associates reported that
recipients treated with mammalian target of
rapamycin (mTOR) inhibitors had a 45% reduction
in overall cancer risk, and they suggested that this
drug can control KS evolution.15 In our center, the
initial step to treating KS patients was to decrease the
immunosuppressive dosage while maintaining graft
function.
PTLD is a heterogeneous group of diseases
characterized by abnormal lymphoid proliferation
after organ transplant and mostly manifested as 
B-cell neoplasia.27 In this study, a higher percentage
of PTLD was found to be the B-cell origin and
monomorphic type. Sixty percent of our cases were
found at higher stages at the time of diagnosis.
The mean time of the development of PTLD was 
64.5 ± 48.8 months after kidney transplant, and this is
not compatible with the reports that state an average
length of 32 months.1,28 Patients who developed
PTLD had mostly CsA-based regimens. There are
conflicting results on whether CsA had a higher
influence on the development of malignant
neoplasms.4,26,29 The rate of allograft involvement by
PTLD was reported to be 17% to 33% in renal
allografts.30 Similarly, we also found 30% of renal
allograft involvement in our patients with PTLD.
The most frequently occurring malignant tumors
in the general population, such as carcinomas of the
colon, breast, and prostate, are not seen frequently
after renal transplant.31 In the review by Kauffman
and associates, percentages of solid nonlymphoma
cancers varied between 32.8% and 80%, and higher
percentages of malignant tumors were seen in the
genitourinary tract, and the lowest were in the
endocrine system.7 Apel and associates reported that
urinary tract malignancies represented the most
frequent malignancies among the nonskin tumors in
their series of 1882 kidney transplant patients.32
Similarly, we detected solid-organ tumors in 32.2%
of our patients, and the most common solid-organ
tumor was urinary tract cancer. Renal cell carcinoma
was reported to be the most frequent posttransplant
urologic tract cancer.33,34 In this study, of the 9 urinary
tract cancers, 3 of them were kidney-graft RCC and 3
were native kidney cancer. Renal allograft carcinoma
was reported in a few case reports.35 It is not entirely
clear whether these allograft tumors occur because of
malignant transformation after transplant or if they
are present at the time of transplant. However, early
diagnosis is necessary to save the graft with limited
surgery.36 We detected the second most common solid-
organ tumor as thyroid papillary microcar cinoma 
in our patients. Two of 4 patients with thyroid
carcinoma had metastatic lymph nodes at the time of
tumor diagnosis. In the English literature, post -
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transplant thyroid cancers were reported as
individual cases.32
Advanced patient age was reported to be a
conventional risk factor for posttransplant malig -
nancies, particularly for SCC.9,37 At the time of tumor
diagnosis, the patients with solid-organ tumors were
older than those with KS and PTLD, but they were
nearly the same age as the skin tumor group patients
in our study. Apel and associates showed similar
findings in which they found skin and nonskin solid
organ tumors at the same age.32 Between the tumor
groups, solid tumors occurred later than the others,
with an average latency period of 99.8 ± 56.9 months.
Based on immunosuppressive regimens, the solid
tumor group differs from others with tacrolimus-
based treatment, but the difference was not
statistically significant.
The overall mortality associated with post -
transplant de novo malignancies is high and
progressively increases with time. Pedotti and
associates reported that the 10-year survival in
kidney recipients without cancer is 92.8% and with
cancer is 56.6%.3 In the 58 patients who developed
skin cancer, there was 50% mortality from cancer.6
Overall 5-year survival after the diagnosis of the
tumor was 81% and 40% for patients with 1
malignant tumor and patients with more than 1
malignant tumor, respectively, in this study.
However, we did not detect a statistically significant
difference in tumor-specific survival between the 4
tumor groups.
In conclusion, regular screening for neoplasms
must be done for all renal allograft recipients for
early diagnosis and treatment.
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